MedTrace Logo

The PEERLESS II Study

NCT06055920 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 1200

Last updated 2026-05-06

No results posted yet for this study

Summary

This study is a prospective, multicenter, randomized controlled trial of the FlowTriever System plus anticoagulation compared to anticoagulation alone for intermediate-risk acute PE.

Conditions

Interventions

DEVICE

FlowTriever System

Mechanical Thrombectomy for pulmonary embolism

DRUG

Anticoagulation Agents

Commercially available/market approved anticoagulation medication including but not limited to: Heparin Sodium, Coumadin, Rivaroxaban, Apixaban, etc. Anticoagulants are a group of medications that decrease your blood's ability to clot.

Sponsors & Collaborators

  • Inari Medical

    lead INDUSTRY

Principal Investigators

  • Frances Mae West, MD · Jefferson Health

  • Jay Giri, MD · Penn Medicine

  • Bernhard Gebauer, MD · Charité University Hospital Berlin

  • Felix Mahfoud, MD · Universitaetsspital Basel

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-11-17
Primary Completion
2026-07-31
Completion
2026-07-31
FDA Device
Yes

Countries

  • United States
  • Belgium
  • Canada
  • Denmark
  • France
  • Germany
  • Poland
  • Spain
  • Switzerland

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06055920 on ClinicalTrials.gov